2019 CCNP Annual Meeting

CCNP 42nd Annual Meeting

June 12 to 15, 2019

McGill University

Downtown Campus

Montreal, Quebec

Dear Colleagues,

This is the first Call for Poster Abstracts for the Canadian College of Neuropsychopharmacology 2019 meeting to be held in the heart of downtown Montréal at Thomson House (McGill University), June 12th-15th, 2019.

Poster submissions should include: (1) Title, (2) List of authors with affiliations, (3) Abstract: introduction, methods, results and conclusions (maximum 300 words). The local organizing committee encourages submissions with a translational component and a mix of junior and senior researchers. We encourage individuals from equity seeking groups such as women, racialized/visible minorities, Aboriginal peoples, persons with a disability and others who reflect the diversity of Canadian society to be included as presenters.

ONLINE REGISTRATION IS NOW CLOSED

Registration is available at the meeting. Only cash and cheques accepted.

We look forward to seeing you in Montréal!

Download or view the 2019 Program.

Acknowledgments

In keeping with CMA guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs and not to individual speakers through an unrestricted educational grant.

The Canadian College of Neuropsychopharmacology appreciates the support of the following sponsors:

GOLD LEVEL SPONSORSHIP
Otsuka Takeda
SILVER LEVEL SPONSORSHIP
Healthy Brains for Healthy Lives Lundbeck
BRONZE LEVEL SPONSORSHIP
McGill Faculty of Medicine Sunovion Brain Canada Foundation Quebec Fonds de recherche
The Canadian College of Neuropsychopharmacology appreciates the ongoing support of Pfizer Canada Inc. for the Heinz Lehman, Innovations in Neuropsychopharmacology and the Young Investigator Award.
  Pfizer  

A Statement by the CCNP

As an organization that embraces diversity and inclusiveness, the CCNP joins many national and international scientific organizations in supporting the scientists and students victimized by the White House executive order that seeks to ban the citizens of seven Muslim-majority countries from entering the USA. Thousands of students and colleagues from diverse countries, cultural, and religious backgrounds benefit from highly stimulating education and research environments in North America. Many of them adopt North America to develop highly productive professional or research careers. Others return to their countries and contribute to their development, thus making the world a better and safer place for all. Travel bans hamper these constructive and beneficial scientific exchanges between nations, and can only make our world more divided and dangerous. The CCNP strongly believes that science transcends divisions based on all kinds of stereotypes, and invites the construction of a reality based on facts, and facts alone, for the benefit of humankind. It is a fact that open science, through the free circulation of students, researchers, ideas, data, and discovery, is now a major engine for the advancement of humankind. Any hindrance to such advancement must be vigorously opposed by the scientific community and, hopefully, will be.

The CAN and SfN have also released their statements about the immigration executive order on their websites:

Statement from CAN-ACN

Statement from SfN

Journal of Psychiatry & Neuroscience

The official journal of the Canadian College of Neuropsychopharmacology
  • The Journal of Psychiatry & Neuroscience has an impact factor of 5.86 (2015 ISI data) and is ranked at #15 out of 140 Psychiatry journals and #29 out of 252 Neuroscience journals, making it the highest ranking open access journal in biological psychiatry.
  • Original research and reviews in basic and clinical science.
  • Articles published in the journal are available free of charge at http://jpn.ca and through PubMed Central.
For more information, visit the website of the Canadian Medical Association.

Revue de psychiatrie & de neuroscience

La revue officielle du Collège canadien de neuropsychopharmacologie
  • Le facteur d'impact de la Revue de psychiatrie et de neuroscience atteint 5,86 (données 2015 de l'ISI), ce qui en fait le journal à accès libre le mieux coté aussi bien dans la catégorie psychiatrie que dans la catégorie neurosciences.
  • Recherche originale et analyses critiques en sciences
      fondamentales et cliniques.
  • Les articles publiés dans ce journal sont accessibles gratuitement au http://jpn.ca/ et via PubMed Central.
Pour obtenir des informations suplémentaires, visitez le site internet de l'Association Médicale Canadienne.